18:25 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) reported that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with osteoarthritis (OA) of the knee. Cingal comprises a single injection of sodium hyaluronate...
01:53 , Jun 20, 2018 |  BC Extra  |  Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) was off $9.62 (21%) to $36.50 in after-hours trading Tuesday after reporting that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with OA of...
18:41 , Jan 11, 2017 |  BC Week In Review  |  Clinical News

Orthovisc-T regulatory update

Anika received CE Mark approval for Orthovisc-T sodium hyaluronate to treat pain and restore function in tendons affected by chronic lateral epicondylosis (tennis elbow). The product comprises a biocompatible formulation of hyaluronic acid. Anika Therapeutics Inc....
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Recombinant human lubricin: Clinical trial data

Top-line data from a double-blind, Italian clinical trial in 39 patients with moderate dry eye disease showed that twice-daily 150 ug/mL recombinant human lubricin eye drops for 7 days followed by instillation as needed for...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Company News

Anika sales and marketing update

Anika launched Cingal in Hungary, Poland, Germany and the Czech Republic to treat pain associated with osteoarthritis. The sodium hyaluronate with triamcinolone hexatonide injection received CE Mark approval in March. Anika declined to provide...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

HaMPCs: Additional Phase IIb data

A single-blind, Chinese Phase IIb trial in 53 patients with OA of the knee showed that 2 intra-articular injections of ReJoin given 3 weeks apart non-significantly reduced WOMAC scores from baseline to week 48 vs....
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Bioventus sales and marketing update

Bioventus launched Supartz FX sodium hyaluronate in the U.S. to treat pain in patients with knee osteoarthritis (OA). The injectable 1% avian-derived sodium hyaluronate is given once weekly for three to five weeks. The...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

HaMPCs: Interim Phase IIb data

Interim data from 24 evaluable patients with OA of the knee in a single-blind, Chinese Phase IIb trial showed that 2 intra-articular injections of ReJoin given 3 weeks apart significantly reduced WOMAC scores from baseline...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

Cingal regulatory update

Anika submitted a PMA in the U.S. for Cingal to treat osteoarthritis (OA) of the knee. Anika also submitted an application for CE Mark approval in the EU at the end of last year. Cingal...
02:09 , Dec 5, 2014 |  BC Extra  |  Company News

Whistleblower suit alleges Sanofi kickback scheme

A former employee of Sanofi (Euronext:SAN; NYSE:SNY) filed a lawsuit alleging that former CEO Christopher Viehbacher and other company executives and managers disbursed $34 million through consultants Accenture and Deloitte in a scheme to induce...